Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Excerpt:...High mutational burden (TMB-H) 2....
Evidence Level:Sensitive: D – Preclinical
Title:
Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors
Excerpt:In PD1 refractory human and murine tumor models with a high TMB, STAR0602 and mSTAR0602 induce potent anti-tumor activity as monotherapy, mediated by selective expansion of Vb CD8+ memory T cells.
DOI:10.1136/jitc-2022-SITC2022.1337